<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28854/keynote-062-pembrolizumab-in-her2-pd-l1-positive-advanced-gastric-cancer?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

KEYNOTE-062: Pembrolizumab in HER2-, PD-L1 Positive Adva...

Name: KEYNOTE-062: Pembrolizumab in HER2-, PD-L1 Positive Adva...
Uploaded: 2019-06-25T07:21:09
Duration: 1 min 16 s
Description: Thomas A. Abrams Senior Physician and Assistant Professor of Medicine at Harvard Medical School tells us his thoughts on KEYNOTE-62. This is investigating pembrolizumab in HER2, PD-L1 positive advanced gastroesophageal cancer.

KEYNOTE-062: Pembrolizumab in HER2-, PD-L1 Positive Advanced Gastric Cancer

00:01:16

Don

3 years 202 Views

Share Add to Report 0 0

Embed (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28854/keynote-062-pembrolizumab-in-her2-pd-l1-positive-advanced-gastric-cancer?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Embed (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://oncologytube.com/videoEmbed/28854/keynote-062-pembrolizumab-in-her2-pd-l1-positive-advanced-gastric-cancer?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit="></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://oncologytube.com/videoEmbed/28854/keynote-062-pembrolizumab-in-her2-pd-l1-positive-advanced-gastric-cancer?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

Link (HTML):

<a href="https://oncologytube.com/v/28854?channelName=obr"><img src="https://oncologytubecom.cdn.ypt.me/videos/video_190625192109_47c0/video_190625192109_47c0.jpg?cache=15669161751678829655">KEYNOTE-062: Pembrolizumab in HER2-, PD-L1  Positive Advanced Gastric Cancer</a>

Link (BBCode):

[url=https://oncologytube.com/v/28854?channelName=obr][img]https://oncologytubecom.cdn.ypt.me/videos/video_190625192109_47c0/video_190625192109_47c0.jpg?cache=15669161751678829655[/img]KEYNOTE-062: Pembrolizumab in HER2-, PD-L1  Positive Advanced Gastric Cancer[/url]

Sign in now!

Permanent Link

URL Friendly (SEO)

Current Time (SEO)

Category:

Gastrointestinal

Description:

Thomas A. Abrams Senior Physician and Assistant Professor of Medicine at Harvard Medical School tells us his
thoughts on KEYNOTE-62. This is investigating pembrolizumab in HER2, PD-L1 positive advanced gastroesophageal cancer.